Moderate Evidence
Research Overview
Pemvidutide Research for Obesity
An evidence-based overview of research examining Pemvidutide in the context of obesity. This page synthesizes findings from peer-reviewed literature.
Research Summary
Phase 2b MOMENTUM trial demonstrated 15.6% weight loss at 48 weeks with 2.4mg dose. Weight loss trajectory had not plateaued, suggesting continued benefit with longer treatment. 78% of weight lost was fat mass, superior to GLP-1-only agents.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Obesity
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Pemvidutide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.